Abstract: Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.

Keywords: degenerative macular disorders, brolucizumab, anti-VEGF, efficacy, safety, intravitreal treatment


中文翻译：

---

Brolucizumab 用于治疗退行性黄斑疾病：临床研究综述

摘要：年龄相关性黄斑变性（AMD）、糖尿病性视网膜病变和视网膜静脉阻塞是发达国家最常见的一些退行性疾病，可导致严重的视力损害。与这些病症相关的并发症的金标准治疗是玻璃体内施用抗血管内皮生长因子（VEGF）药物。Brolucizumab 是一种新开发的人源化单克隆抗体单链片段，可结合所有 VEGF-A 同工型，最近被批准用于治疗新生血管性 AMD。玻璃体内注射 brolucizumab 有望通过减少就诊次数实现可比的治疗结果，从而减轻 nAMD 患者的治疗负担。它也有望用于治疗更具挑战性的黄斑病，如糖尿病性黄斑水肿 (DMO)。本综述的目的是描述 brolucizumab 的特殊药理学特性，并展示有关其治疗退行性黄斑疾病的有效性和安全性的最重要的临床试验和现实世界研究的结果。

关键词:退行性黄斑疾病, brolucizumab, 抗 VEGF, 疗效, 安全性, 玻璃体内治疗